EmCyte Corporation

06/01/2026

Emcyte Corporation, in collaboration with Rocky Vista University, is conducting an important clinical study focused on the use of Platelet-Rich Plasma (PRP) for knee conditions.

Qualified participants may have the opportunity to take part in this research alongside renowned physicians and their team of experts dedicated to advancing regenerative medicine.


co

If you are experiencing knee pain and you are in the Davie Florida, Naples Florida or Boulder Colorado area and would like to learn whether you qualify for this study, we encourage you to contact your nearest location for more information.

ClinicalResearch

05/29/2026

Inside EmCyte Corporation, innovation is driven by research, precision, and continuous scientific advancement. From modern laboratory analysis to advanced regenerative biologic protocols, our team is committed to helping move regenerative medicine forward through evidence-based studies and technology.

Our state-of-the-art labs and scientific directors work continuously on research involving PRP, bone marrow concentrate, adipose biologics, and regenerative treatment optimization supporting physicians with advanced protocols, data analysis, and clinical education.

At EmCyte, science is not just studied — it’s applied to help improve the future of regenerative medicine.
Learn more at: emcyte.com

05/27/2026

WHY CHOOSE US?
LEADING IN VALIDATED SUPRAPHYSIOLOGIC BIOLOGICS WITH MEASURABLE OUTCOMES.

EmCyte Corporation is the world-wide leader in validated supraphysiologic biologics, delivering advanced regenerative technologies engineered for measurable clinical outcomes.

Through precision biologic processing, point-of-care validation, physician education, and scientific innovation, EmCyte continues to lead the future of non-surgical regenerative medicine and patient-centered biologic therapies.

🔹Tailored clinical solutions.
🔹Seamless process processing techniques.
🔹Dedicated to durable outcomes.

Lear more by visiting our website at: emcyte.com

05/27/2026

05/26/2026

Welcome to EmCyte Insights/ weekly mini journal club.
This week, we highlight a 2025 systematic review, meta-analysis, and meta-regression published in The American Journal of Sports Medicine, evaluating a critical question in orthobiologics: does platelet concentration explain why PRP outcomes vary so much in lateral epicondylitis?

Lateral epicondylitis, commonly known as tennis elbow, affects up to 3% of adults, especially between ages 35–55. Although many cases improve over time, persistent disease can lead to chronic pain, reduced grip strength, functional limitation, and work-related disability. PRP has been used as a biologic strategy because platelets release growth factors and anti-inflammatory mediators that may support tenocyte activity, collagen synthesis, and tendon repair. However, clinical results have been inconsistent—possibly because not all PRP is truly “high-dose” PRP.
This analysis included 13 randomized controlled trials with 791 patients.

Studies were separated into high-dose PRPand low-dose PRP, where high-dose PRP was defined as >3× platelet concentration over whole blood or a documented supraphysiologic platelet dose.
The results were very clear. When all PRP studies were pooled, PRP showed a modest benefit in pain reduction compared with controls (VAS mean difference: −0.72; p = 0.009).

But when separated by dose, the difference became much more obvious: high-dose PRP significantly improved pain compared with alternative treatments (VAS MD: −1.31; p < 0.001), while low-dose PRP showed no meaningful benefit (VAS MD: 0.08; p = 0.79). Importantly, platelet concentration alone explained 58.5% of outcome variability across studies.

🔹Conclusion: PRP efficacy in lateral epicondylitis may depend heavily on platelet dose. For clinicians, the message is simple: dose matters, and supraphysiologic platelet concentration should be verified whenever possible.

Article link: https://lnkd.in/eaNnWC4p

05/21/2026

We were truly honored to have had the opportunity to welcome the Latimer Fellows to EmCyte Corporation and provide a behind-the-scenes look at our facility, technology, and commitment to advancing regenerative medicine.

It was inspiring to connect with such accomplished entrepreneurs, innovators, and forward-thinking leaders who continue creating ideas, businesses, and solutions that positively impact industries around the world.

The Lewis Latimer Fellowship Program is designed to provide special access and mentorship to an exceptional small group of visionary innovators.

🙏 Thank you for visiting and sharing your vision, experience, and passion for innovation with our team. The future is built by minds willing to create beyond limits.

05/19/2026

We are truly grateful to everyone who participated in this amazing conference, all of those who shared their expertise, and contributed to such an engaging hands-on educational environment.

From mastering the EmCyte ASPIRA™ System to exploring the science behind personalized bio-formulations, this training reinforced the importance of precision, consistency, and evidence-based protocols in achieving better patient outcomes.

The hands-on sessions covering blood draw techniques, centrifugation workflows, platelet optimization, and tailored PRP applications made this an invaluable experience for every attendee. It’s inspiring to see so many professionals committed to advancing regenerative medicine through education and clinical excellence.

Thank you to everyone who made this training day such a success. Together, we continue elevating skills, standardizing results, and pushing regenerative aesthetics forward.

05/18/2026

Join EmCyte’s Regenerative Edge Webinar exploring an advanced biologic strategy for managing frozen shoulder using hydrodilatation enhanced with PRP and concentrated plasma proteins (CPP).

This session integrates clinical experience with underlying biologic mechanisms, highlighting how orthobiologic therapies can support capsular remodeling, reduce inflammation, and improve functional outcomes in adhesive capsulitis.

Attendees will gain insight into real-world patient treatments, procedural techniques, and evolving regenerative protocols designed to optimize recovery and restore mobility.

🔹TOPIC: EmCyte Regenerative Edge Webinar Series : A Biologic Approach to Frozen Shoulder: Hydrodilatation With PRP and Concentrated Plasma Proteins

🔹MODERATOR: Natalie Stephens, PhD – Scientific Director, Biofyl Scientific Research Laboratories, Expert in Regenerative Medical Device Testing

🔹FEATURED SPEAKERS: Erek Latzka, MD Regenerative Orthopedics & MSK Specialist with an extensive clinical expertise in the use of regenerative biologics for musculoskeletal care. Sina Farzaneh, PhD – Multidisciplinary Scientist and Innovator in Biomedical Engineering, Tissue Engineering, and Regenerative Medicine

🔹WHAT YOU’LL LEARN:
• Clinical applications of PRP and concentrated plasma proteins in adhesive capsulitis
• Biologic rationale for hydrodilatation combined with orthobiologics, including modulation of inflammation, fibrosis, and capsular stiffness
• Patient selection, staging considerations, and treatment timing for optimal outcomes
• Procedural techniques and practical insights from real-world cases treated with PRP and CPP
• Strategies to enhance shoulder mobility, reduce pain, and support tissue healing

🔹WHO SHOULD ATTEND:
Orthopedic and sports medicine physicians, pain management specialists, physical medicine and rehabilitation providers, regenerative medicine practitioners, and clinicians interested in orthobiologic approaches for musculoskeletal conditions such as frozen shoulder.

🔹Scan the QR code or click our link in our bio to register.